{"nctId":"NCT01265849","briefTitle":"Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity","startDateStruct":{"date":"2010-12","type":"ACTUAL"},"conditions":["Squamous Cell Carcinoma of the Oral Cavity","Squamous Cell Carcinoma of the Soft Palate"],"count":928,"armGroups":[{"label":"LI + CIZ + SOC","type":"EXPERIMENTAL","interventionNames":["Biological: LI","Drug: Cyclophosphamide","Drug: Indomethacin","Dietary Supplement: Zinc","Procedure: Surgery","Drug: Cisplatin","Radiation: Radiotherapy"]},{"label":"Standard of Care (SOC) only","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Surgery","Drug: Cisplatin","Radiation: Radiotherapy"]},{"label":"LI + SOC","type":"EXPERIMENTAL","interventionNames":["Biological: LI","Procedure: Surgery","Drug: Cisplatin","Radiation: Radiotherapy"]}],"interventions":[{"name":"LI","otherNames":["Multikine","Leukocyte interleukin, injection"]},{"name":"Cyclophosphamide","otherNames":[]},{"name":"Indomethacin","otherNames":[]},{"name":"Zinc","otherNames":["Multivitamins"]},{"name":"Surgery","otherNames":[]},{"name":"Cisplatin","otherNames":[]},{"name":"Radiotherapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria (main):\n\n* Untreated SCCHN of oral cavity (anterior tongue, floor of mouth, cheek)/soft palate, categories T1N1-2M0,T2N1-2M0,T3N0-2M0,T4N0-2M0 (T4 allowed only if invasion of mandible is negligible i. e. 5mm or less) scheduled for SOC\n* Primary tumor and any positive node(s) measurable in 2 dimensions\n* Normal immune function\n* No immunosuppressives with 1 year of entry\n* KPS\\>70/100\n* Age\\>18\n* Male or Female (non-pregnant)\n* Life expectancy \\>6 months\n* Able to take oral medication\n* Able to provide informed consent\n\nExclusion Criteria (main):\n\n* Subjects to be treated with other than SOC\n* Tumor invasion of bone (also see inclusion criteria)\n* Tumor classifications T1N0, T2N0, T4N3, any TN classification with M1\n* Tumors in locations other than those specified in inclusion criteria\n* Active peptic ulcer (or on full-dose therapeutic anti-coagulants)\n* Prior resection of jugular nodes ipsilateral to tumor\n* Acute or chronic viral, bacterial immune or other disease associated with abnormal immune function\n* Subjects on hemodialysis or peritoneal dialysis; or having a history of\n* History of asthma, allergy to fluoroquinolone antibiotics, congestive heart failure, or on hemodialysis or peritoneal dialysis\n* Any condition that in the opinion of the investigator would cause the subject to be unable to participate or tolerate the protocol regimen\n* Failure to meet inclusion criteria","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"OS was assessed using Kaplan-Meier life-table using a log rank test and confirmed further with tumor stage, tumor location, and geographic stratified log rank test. Both Stratified and unstratified log rank test are presented with the unstratified log rank test constituting the primary analysis. A two-sided p-value of 0.05 or less was considered statistically significant for comparing the two groups (i.e., Study comparator arms: LI+CIZ+SOC vs. SOC alone). Interim analyses were performed (by the iDMC) periodically throughout the study to assess safety, sample size and futility.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.3","spread":null},{"groupId":"OG001","value":"58.1","spread":null},{"groupId":"OG002","value":"52.9","spread":null}]}]}]},{"type":"PRIMARY","title":"OS in Low Risk Subjects","description":"OS was assessed using Kaplan-Meier life-table using a log rank test and confirmed further with tumor stage, tumor location, and geographic stratified log rank test. Both Stratified and unstratified log rank test are presented with the unstratified log rank test constituting the primary analysis. A two-sided p-value of 0.05 or less was considered statistically significant for comparing the two groups (i.e., Study comparator arms: LI+CIZ+SOC vs. SOC alone). Low-risk assessment and data analysis was never performed during the study and was done only after database lock.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101.7","spread":null},{"groupId":"OG001","value":"68.2","spread":null},{"groupId":"OG002","value":"55.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Regional Control (LRC)","description":"LRC is defined as the number of months from randomization to the date of documented local or regional failure (recurrence or progression) or date of last follow-up or death. LRC failure includes the reappearance (recurrence) of disease (at the original tumor sites), progressive disease (but not distant metastases), or any new disease (including new disease in lymph nodes), above the clavicle, not present at baseline. This is the traditional RTOG measure of local-regional control, also referred to as Freedom from Local Progression.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"LRC in Low Risk Subjects","description":"LRC is defined as the number of months from randomization to the date of documented local or regional failure (recurrence or progression) or date of last follow-up or death. LRC failure includes the reappearance (recurrence) of disease (at the original tumor sites), progressive disease (but not distant metastases), or any new disease (including new disease in lymph nodes), above the clavicle, not present at baseline. This is the traditional RTOG measure of local-regional control, also referred to as Freedom from Local Progression. Low risk assessment and data analysis was never performed during the study and was done only after database lock.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS is defined as the number of months from randomization to the date of first documented, progressive disease (any tumor recurrence, any new disease above clavicle or distant metastases) or the date of last follow-up or death. Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of the longest dimension (LD) of target lesions, taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null},{"groupId":"OG001","value":"37.0","spread":null},{"groupId":"OG002","value":"45.5","spread":null}]}]}]},{"type":"SECONDARY","title":"PFS in Low Risk Subjects","description":"PFS is defined as the number of months from randomization to the date of first documented, progressive disease (any tumor recurrence, any new disease above clavicle or distant metastases) or the date of last follow-up or death. Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of the longest dimension (LD) of target lesions, taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more new lesions. Low risk assessment and data analysis was not performed during the study and was performed only after database lock.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.4","spread":null},{"groupId":"OG001","value":"68.2","spread":null},{"groupId":"OG002","value":"51.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life by EORTC QLQ-C30 Global Health Status [GHS] at Month 2","description":"The European Organisation for Research and Treatment of Cancer Quality of Life Questionaire C-30 Version 3.0 (EORTC QLQ-C30) V3.0 is composed of both multi-item scales and single-item measures. The Global Health Scale/QoL multi-item scale \\[GHS\\] is a comprised of two Items: Item 29 \"How would you rate your overall health during the past week?\", and item 30: \"How would you rate your overall quality of life during the past week?\". Both items are 7 point scales ranging from a score of 1 (very poor) to 7 (Excellent). The GHS is constructed by averaging Items 29 and 30 to obtain a raw score (RS). The RS is then transformed to a 0-100 scale by the equation GHS=100\\*\\[(RS-1)/6\\]. A higher score represents a higher (\"better\") QoL. Change in GHS is calculated as Observed - Baseline, so a positive change in GHS is improved QoL. Treatment comparisons are active treatment arms minus SOC, so a positive difference favors active treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"1.82"},{"groupId":"OG001","value":"7.95","spread":"3.03"},{"groupId":"OG002","value":"3.29","spread":"1.83"}]}]}]},{"type":"SECONDARY","title":"Quality of Life by EORTC QLQ-C30 Global Health Status [GHS] at Month 36","description":"The European Organisation for Research and Treatment of Cancer Quality of Life Questionaire C-30 Version 3.0 (EORTC QLQ-C30) V3.0 is composed of both multi-item scales and single-item measures. The Global Health Scale/QoL multi-item scale \\[GHS\\] is a comprised of two Items: Item 29 \"How would you rate your overall health during the past week?\", and item 30: \"How would you rate your overall quality of life during the past week?\". Both items are 7 point scales ranging from a score of 1 (very poor) to 7 (Excellent). The GHS is constructed by averaging Items 29 and 30 to obtain a raw score (RS). The RS is then transformed to a 0-100 scale by the equation GHS=100\\*\\[(RS-1)/6\\]. A higher score represents a higher (\"better\") QoL. Change in GHS is calculated as Observed - Baseline, so a positive change in GHS is improved QoL. Treatment comparisons are active treatment arms minus SOC, so a positive difference favors active treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.64","spread":"1.82"},{"groupId":"OG001","value":"10.79","spread":"2.85"},{"groupId":"OG002","value":"6.33","spread":"1.80"}]}]}]},{"type":"SECONDARY","title":"EORTC Quality of Life Questionnaire (QLQ) - Head & Neck Cancer Module: QLQ-H&N35 at Month 2","description":"The European Organisation for Research and Treatment of Cancer Quality of Life Questionaire C-30 Version 3.0 supplementary Head \\& neck cancer module (EORTC QLQ-C30 - QLQ H\\&N35) items 1-4 make up the symptom score for pain, items 5-8 for swallowing. The 4 pain questions score: \"pain in your mouth, pain in your jaw, soreness in your mouth, a painful throat?\" The 4 swallowing questions score \"problems swallowing: liquids, pureed food, solid food, choking? Item are scored as 1 (Not at all) to 4 (Very much). Each symptom scale is constructed by averaging the 4 items to obtain a raw score (RS). The RS is then transformed to a 0-100 scale by the equation symptom score (pain or swallowing)=100\\*\\[(RS-1)/3\\]. A high score for these symptom scales represents a high level of symptoms.Change in symptom is calculated as Observed - Baseline, so a negative change is reduced symptomatology . Treatment comparisons are active treatment arms minus SOC, so a negative difference favors active treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.75","spread":"1.66"},{"groupId":"OG001","value":"-2.80","spread":"2.77"},{"groupId":"OG002","value":"-3.81","spread":"1.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.11","spread":"1.88"},{"groupId":"OG001","value":"6.29","spread":"3.13"},{"groupId":"OG002","value":"7.31","spread":"1.89"}]}]}]},{"type":"SECONDARY","title":"EORTC Quality of Life Questionnaire (QLQ) - Head & Neck Cancer Module: QLQ-H&N35 at Month 36","description":"The European Organisation for Research and Treatment of Cancer Quality of Life Questionaire C-30 Version 3.0 supplementary Head \\& neck cancer module (EORTC QLQ-C30 - QLQ H\\&N35) items 1-4 make up the symptom score for pain, items 5-8 for swallowing. The 4 pain questions score: \"pain in your mouth, pain in your jaw, soreness in your mouth, a painful throat?\" The 4 swallowing questions score \"problems swallowing: liquids, pureed food, solid food, choking? Item are scored as 1 (Not at all) to 4 (Very much). Each symptom scale is constructed by averaging the 4 items to obtain a raw score (RS). The RS is then transformed to a 0-100 scale by the equation symptom score (pain or swallowing)=100\\*\\[(RS-1)/3\\]. A high score for these symptom scales represents a high level of symptoms.Change in symptom is calculated as Observed - Baseline, so a negative change is reduced symptomatology . Treatment comparisons are active treatment arms minus SOC, so a negative difference favors active treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.47","spread":"1.66"},{"groupId":"OG001","value":"-8.63","spread":"2.61"},{"groupId":"OG002","value":"-8.42","spread":"1.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.90","spread":"1.89"},{"groupId":"OG001","value":"1.66","spread":"2.96"},{"groupId":"OG002","value":"8.94","spread":"1.86"}]}]}]},{"type":"SECONDARY","title":"Statistical Comparisons of Time-to-event Outcomes (OS, LRC, PFS) Were Repeated for Varying Levels of Histopathology (HP) Markers in Low Risk Subjects","description":"HP analysis was performed in a blinded manner by a central pathology laboratory at the end of the study on available samples. To examine potential effects of HP markers on time-to-event efficacy outcomes (OS, LRC, PFS), participants were classified by HP marker levels: 20 HP markers were classified as (low, medium, high), 2 HP ratios as (low, medium, high) and 14 HP combinations as (low, high), resulting in 94 (20\\*3+2\\*3+2\\*14) possible treatment comparisons of LI + CIZ + SOC to SOC. A total of 282 (94 x 3 efficacy outcomes) statistical tests (Cox proportional hazards regressions to test for a significant treatment effect in the model) were made. Significance (two-sided p\\<0.05 favoring LI + CIZ + SOC) were reported under LI + CIZ + SOC. Significant test results favoring SOC were reported under SOC. The total number of statistical comparisons between LI + CIZ + SOC and SOC (282) is reported under both arms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"POST_HOC","title":"Tumor Response by RECIST 1.0","description":"Tumor response is evaluated per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) and confirmed by pathology at surgery. For target lesions as assessed by MRI or CT: Complete Response (CR) is disappearance of all target and non-target lesions, no new tumors, and normalization of tumor marker level. Partial Response (PR), \\>=30% decrease in the sum of the longest diameter (LD) of target lesions taken as a reference the baseline sum of LDs, and no new tumors. Objective response = CR + PR. Response was assessed to LI treatment and compared to controls (SOC) from randomization to surgery in the ITT population for recurrence.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"POST_HOC","title":"Tumor Response by RECIST 1.0 in Low Risk Subjects","description":"Tumor response was evaluated per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). For target lesions as assessed by MRI or CT: Complete Response (CR) is disappearance of all target and non-target lesions, no new tumors, and normalization of tumor marker level. Partial Response (PR), \\>=30% decrease in the sum of the longest diameter (LD) of target lesions taken as a reference the baseline sum of LDs, and no new tumors. Objective response = CR + PR. Response was assessed to LI treatment and compared to controls (SOC) from randomization to surgery in the lower risk ITT population for recurrence.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"POST_HOC","title":"Survival by Objective Response (CR+PR)","description":"Survival is assessed as dead or alive at last follow-up. Tumor response is evaluated per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). For target lesions as assessed by MRI or CT: Complete Response (CR) is disappearance of all target and non-target lesions, no new tumors, and normalization of tumor marker level. Partial Response (PR), \\>=30% decrease in the sum of the longest diameter (LD) of target lesions taken as a reference the baseline sum of LDs, and no new tumors. Objective response = CR + PR.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"204","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"197","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"POST_HOC","title":"Survival by Objective Response (CR+PR) in Low Risk Subjects","description":"OS is assessed as dead or alive at last follow-up. Tumor response is evaluated per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). For target lesions as assessed by MRI or CT: Complete Response (CR) is disappearance of all target and non-target lesions, no new tumors, and normalization of tumor marker level. Partial Response (PR), \\>=30% decrease in the sum of the longest diameter (LD) of target lesions taken as a reference the baseline sum of LDs, and no new tumors. Objective response = CR + PR.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"POST_HOC","title":"Overall Survival by Objective Response (CR+PR) in Low Risk Subjects","description":"OS is assessed using Kaplan-Meier life-table using an unstratified log rank test and a stratified log rank test, stratified by tumor stage, tumor location, and geographic region. Alive at last follow-up was was censored.\n\nTumor response is evaluated per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). For target lesions as assessed by MRI or CT: Complete Response (CR) is disappearance of all target and non-target lesions, no new tumors, and normalization of tumor marker level. Partial Response (PR), \\>=30% decrease in the sum of the longest diameter (LD) of target lesions taken as a reference the baseline sum of LDs, and no new tumors. Objective response = CR + PR.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":216,"n":383},"commonTop":["Weight decreased","Mucosal inflammation","Radiation skin injury","Anaemia","Stomatitis"]}}}